Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 23,13:30-17:00
Peptide Drug R&D Frontier Session
Stay tuned
13:30-14:00 GLP‑1 R&D Journey and Outlook
Wang Qinghua, Founder, Chairman & CEO, Guangzhou Innogen Pharmaceutical Group Co., Ltd.
14:00-14:20 Precise delivery of anti-tumor molecules
Changqing Su, Chief Scientist, Pharmaceutical Research Institute, Fosun Wanbang Group
14:20-14:40 Cyclic Peptide Discovery Integrating mRNA Display and AI
Cui Haifeng, CSO, Shanghai Highline Therapeutics, Inc.
14:40-15:00 Recent R&D trends and clinical progresses of small format drug conjugates
Jun Shao, Chief Technology Officer (CTO), Coherent Biopharma (Suzhou) Co.
15:00-15:20 Integrated CMC Solutions to accelerate Peptide Drug Discovery and Development
William Fang, Vice President, Head of Oligonucleotide & Peptide Development, WuXi TIDES
15:20-15:40 Break
15:40-16:00 AI‑Designed Cyclic Peptide Drugs to Tackle Undruggable Targets
Zhang Genwei, Peptide R&D Lead, XtalPi Holdings Limited
16:00-16:20 Screening and Evaluation of Peptide Drugs from GLP‑1 to Multi‑target Agonists
Wang Xinyuan, FAS Manager, China Application, Revvity
16:20-17:00 Round Table Dialogue:China's Innovative Peptide Drugs Going Global – Opportunities, Challenges, and the Future
Liu Jiang (Moderator), Vice President & General Manager, Greater China, Revvity
Cao Chunlai, CEO, Federal Biotechnology (Zhuhai Hengqin)
Jun Shao, Chief Technology Officer (CTO), Coherent Biopharma (Suzhou) Co.
Chen Xiaoxin, Vice President, Guangdong Zhongsheng Pharmaceutical ; Co‑Founder, Chairman & CEO, Guangdong Zhongsheng Ruichuang Biological Technology
Wenjie Xu, Senior Vice President Chief Commercial Officer, Innogen